Finance

Pharmalot

Pharmalittle: A campaign downplays concerns over antibiotics given animals; U.K. parents step up fight over Vertex drug

By Ed Silverman

Pharmalot

Pharmalittle: Valeant suffers a setback; CVS will use the Postal Service to deliver meds to your door

By Ed Silverman

advertisement

Eric Schmidt

Biotech

CAR-T startup Allogene Therapeutics picks up veteran analyst Eric Schmidt as CFO

By Adam Feuerstein

advertisement

Pharmalot

Pharmalittle: Celgene issues a mea culpa; Azar remains adamant that Medicare should not negotiate prices

By Ed Silverman

Pharmalot

Pharmalittle: An ALS drug may become available under ‘right to try’; Takeda shareholders look to derail Shire deal

By Ed Silverman

Retail Health Clinics

First Opinion

How early retail health clinics set the stage for today’s mega-mergers

By Hal Rosenbluth and Peter Miller

Pharmalot

Pharmalittle: Novo Nordisk plans thousands of layoffs; Will former Allergan CEO return as chairman?

By Ed Silverman

advertisement

Pharmalot

Pharmalittle: Pfizer’s Hospira unit has another recall problem; Carl Icahn buys Allergan stock

By Ed Silverman

advertisement

Hong Kong Stocks

Biotech

Can Hong Kong lure biotech without inflating a bubble?

By Rebecca Robbins

Lisa Suennen 01

Business

The gatekeeper: If you want to make it big in health care, it’ll help to get past Lisa Suennen first

By Rebecca Robbins

Pharmalot

Allergan is urged to split CEO and chairman jobs by ‘disappointed’ hedge funds

By Ed Silverman

Pharmalot

Pharmalittle: Takeda shareholders call Shire deal ‘madness’; Mylan wins biosimilar approval in the U.S.

By Ed Silverman

First Opinion

Every state needs a database with all health insurance claims, not just some

By John Freedman

Pharmalot

Pharmalittle: Trump predicts ‘massive’ price cuts soon; Gilead will advertise its HIV prevention pill

By Ed Silverman

Pharmalot

Pharmalittle: Did White House official violate ethics rules? Purdue execs knew about OxyContin abuse

By Ed Silverman

Handshake

First Opinion

The health care industry is being transformed, one deal at a time

By Thad Kresho

Pharmalot

Pharmalittle: A battered Celgene does a big stock buyback; Senate committee to vote on pharmacy gag clause bill

By Ed Silverman

VC Health Boot Camp

Health

A new VC firm will invest in your startup — and pay for you to get therapy and acupuncture

By Rebecca Robbins

Pharmalot

Pharmalittle: Celgene exec departure rattles investors; which biotechs are juicy takeover targets?

By Ed Silverman

Adam's Take

After watching Trump’s drug speech, investors poured big money into biotech funds

By Adam Feuerstein

Business

Vetting AI, early IPOs, and an absence of suits: a conversation with a biotech VC at Andreessen Horowitz

By Rebecca Robbins

Adam's Take

Biotech stocks open higher Monday on ‘Trump bump’

By Adam Feuerstein

Pharmalot

Pharmalittle: Roche suffers a setback in a cancer trial; Trump wants to shift Medicare B drugs to Part D

By Ed Silverman

Business

Eli Lilly acquires small biotech for $1.6 billion to strengthen cancer immunotherapy pipeline

By Adam Feuerstein

Business

Experts puzzle over Partners-Harvard Pilgrim merger talks

By Priyanka Dayal McCluskey — Boston Globe

Andy Plump Takeda

Pharmalot

Takeda R&D chief says the Shire deal will accelerate plans by three to five years

By Ed Silverman

Pharmalot

Pharmalittle: Takeda finally makes a deal for Shire; Congress probes insulin pricing today

By Ed Silverman

Hong Kong Financial Markets

Biotech

Ascletis becomes the first biotech seeking to go public in Hong Kong under new rules

By Rebecca Robbins

Biotech China

First Opinion

Strong action is needed to preserve the competitiveness of America’s life-science industries

By Joe Kennedy